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Abstract
We have previously demonstrated that olanzapine-induced desensitization of 5-HT2A receptor-stimulated
phospholipase C (PLC) activity is associated with increases in RGS7 protein levels both in vivo and in cells
in culture, and the increase in RGS7 is dependent on activation of the JAK-STAT pathway in cells in
culture. In the present study, we found that desensitization of 5-HT2A receptor-stimulated PLC activity
induced by olanzapine is dependent on activation of the JAK-STAT pathway. Similar to olanzapine,
clozapine-induced desensitization of 5-HT2A receptor signalling is accompanied by increases in RGS7 and
activation of JAK2. Treatment with the selective 5-HT2A receptor antagonist MDL 100907 also increased
RGS7 protein levels and JAK2 activation. Using a JAK2 inhibitor AG490, we found that clozapine and
MDL 100907-induced increases in RGS7 are dependent on activation of the JAK-STAT pathway.
Olanzapine, clozapine, and MDL 100907 treatment increased mRNA levels of RGS7. Using a chromatin
immunoprecipitation assay we found STAT3 binding to the putative RGS7 promoter region. Taken
together, olanzapine-induced activation of the JAK-STAT pathway, and STAT3 binding to the RGS7 gene
could underlie the increase in RGS7 mRNA which could subsequently increase protein expression.
Furthermore, the increase in RGS7 protein could play a role in the desensitization of 5-HT2A receptor
signalling by terminating the activated Gaq/11 proteins more rapidly. Overall, our data suggest that the
complete desensitization of 5-HT2A receptor-stimulated PLC activity by olanzapine, clozapine and
MDL 100907 requires activation of the JAK-STAT pathway, which in turn increases RGS7 expression
probably by direct transcriptional activity of STAT3.
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Introduction
Atypical antipsychotics like clozapine and olanz-
apine (dibenzopyridine derivatives) represent a rela-
tively new generation of antipsychotics with fewer
incidences of negative side-effects such as extra-
pyramidal side-effects (EPS) (Meltzer, 1995). Although,
atypical antipsychotics have a diverse receptor binding
profile, 5-HT-receptor-based mechanisms have been
postulated to play a critical role in the action of the
atypical antipsychotic drugs (Willins et al., 1999).
However, the process by which these drug–receptor
interactions translate into long-term cellular adaptive
changes resulting in antipsychotic efficacy is unknown.
Atypical antipsychotic drugs bind with high affinity
to 5-HT2A receptors and desensitize 5-HT2A receptor
signalling (Deutch et al., 1991 ; Meltzer, 1995 ; Seeger
et al., 1995). Although, desensitization of 5-HT2A re-
ceptor signalling by atypical antipsychotics is reported
to be associated with down-regulation and inter-
nalization (Willins et al., 1999) ; the molecular mech-
anisms that underlie these changes are not well
understood. Activation of 5-HT2A receptors stimulates
activation of Gaq/11, which in turn activates effector
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enzymes including phospholipase C (PLC). PLC
catalyses release of diacylglycerol (DAG) and inositol
triphosphate from phosphatidyl inositol bisphosphate
(PIP2). The released inositol phosphate (IP) can be
measured as an index of 5-HT2A receptor signalling
activity. In addition to these integral components of
the receptor signalling system, regulators of G protein
signalling (RGS) proteins modulate signalling of
several G protein-coupled receptors (GPCR) (Koelle
and Horvitz, 1996). RGS proteins can regulate G-
protein signalling by functioning as GTPase-activating
proteins (GAPs). GAP activity can hasten the termin-
ation of a signal upon removal of a stimulus, attenuate
a signal either as a feedback inhibitor or in response
to a second input, promote regulatory association
of other proteins, or redirect signalling within a G-
protein signalling network (Ross and Wilkie, 2000).
RGS4 and RGS7 are highly enriched in various brain
regions including frontal cortex and are reported to be
GAPs for Gaq/11-associated 5-HT2A receptor signalling
(Larminie et al., 2004). Khawaja et al. (1999) have
extensively characterized cellular co-localization of
RGS7 with Gaq/11 immunohistochemically throughout
the adult rat brain and reported a heterogeneous
and overlapping regional distribution (Khawaja et al.,
1999).
We have previously reported that desensitization of
5-HT2A receptor signalling with chronic treatment of
olanzapine is accompanied by activation of STAT3
and an increase in RGS7 protein levels in rat frontal
cortex (Muma et al., 2007). In addition, we found that
24-h treatment with olanzapine causes desensitization
of 5-HT2A receptor signalling and an increase in
membrane-associated RGS7 protein that is dependent
on activation of the JAK2-STAT3 pathway in A1A1v
cells, a cell line endogenously expressing the 5-HT2A
receptor signalling components (Singh et al., 2007).
However, whether activation of the JAK-STAT path-
way is necessary for olanzapine-induced desensitiz-
ation and the mechanisms by which activation of the
JAK-STAT pathway increase RGS7 protein are not
currently known. Therefore, it is important to deter-
mine not only the role of the JAK-STAT pathway
but also the mechanisms underlying up-regulation
of RGS7 protein in response to antipsychotic treatment
to help identify new targets for therapeutic inter-
vention.
Increases in RGS7 protein levels could be mediated
by several mechanisms, for example RGS7 binding to
Gb5 is reported to increase stability of each protein
(Chen et al., 2003 ; Krumins et al., 2004) such that an
increase in Gb5 could increase RGS7 protein levels.
Another possible mechanism is a direct increase in
transcription of RGS7 thereby increasing RGS7 mRNA
levels. We previously reported that inhibition of the
JAK-STAT pathway completely blocked the increase
in RGS7 protein levels by olanzapine (Singh et al.,
2007). Although, transcriptional activity of STAT3
has been extensively reported for various genes
(Aaronson and Horvath, 2002 ; Kisseleva et al., 2002;
Schindler, 2002), STAT3 has not been identified as a
transcription factor for RGS7. STAT3-mediated regu-
lation of gene expression is associated with the pres-
ence of the consensus element TTCN2-4GAA upstream
of the transcription start site (Ehret et al., 2001;
Wrighting and Andrews, 2006). Genomic sequence
analysis of rat RGS7 revealed that there are multiple
sets of TTCN2-4GAA sequences. Thus, it is possible that
STAT3 is a transcription factor for the RGS7 promoter.
Based on our previous reports that the olanzapine-
induced increases in RGS7 protein levels are depen-
dent on activation of the JAK-STAT pathway, we
hypothesize that STAT3 is a transcription factor for
RGS7 and is directly responsible for the increase in
RGS7 protein levels by olanzapine treatment. In this
study,we also examinedwhether another atypical anti-
psychotic, clozapine and a selective 5-HT2A receptor
antagonist, MDL 100907, also activate the JAK-STAT
pathway and increase RGS7 expression. Last, we
determined whether activation of the JAK-STAT
pathway is necessary for desensitization of 5-HT2A
receptor signalling by these atypical antipsychotics.
Method
Drugs
Olanzapine and AG490 were purchased from Torrent
Research Chemicals Inc. (ON, Canada). MDL 100907
was kindly provided by Sanofi Aventis (Bridgewater,
NJ, USA). Clozapine was purchased from Tocris
(Ellisville, MO, USA). Olanzapine was dissolved in
20% glacial acetic acid and the pH was adjusted to
6.5 with 10 M NaOH as described previously (Singh
et al., 2007). AG490, MDL 100907 and clozapine were
dissolved in 100% DMSO to obtain the desired con-
centration for individual treatments with each drug.
(–)1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane
(DOI) was purchased from Sigma-Aldrich (St Louis,
MO, USA). HBSS mix (1r HBSS, 20 mM LiCl2, 20 mM
Hepes) was used to dissolve DOI. A stock solution of
100 mM clozapine was prepared in DMSO. For each
treatment group an equal volume of drug or vehicle
(10 ml), was added to 10 ml cell culture media. Fur-
thermore, an equal volume of DMSO was added for
each treatment group.
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Cell culture
A1A1v cells, a cortical cell line, that endogenously
expresses 5-HT2A receptors and its downstream com-
ponents, were used for all experiments. Cells were
grown in the charcoal-treated serum to diminish
serotonin in the media 24 h before treatment with
olanzapine, clozapine, or MDL 100907. Cells were
treated with either vehicle or drugs for 24 h.
Cell fractionation
Cell lysates were separated into membrane and
cytosol fractions using centrifugation as previously
described (Singh et al., 2007 ; Tucker, 2004). All sub-
sequent solutions contained phosphatase inhibitors.
Briefly, cells were washed once with PBS containing
phosphatase inhibitors, followed by incubation in a
buffer containing 0.25 M sucrose, 50 mM Tris–HCl,
5 mM EDTA, and protease inhibitor cocktail (Sigma-
Aldrich) for 15 min on ice before lifting them with a
cell scrapper. Cells were spun at 500 g at 4 xC to re-
move cell debris and then sonicated three times for
10 s to make a cell homogenate. The homogenate was
spun at 100 000 g for 45 min at 4 xC to produce a pellet,
which is composed of membrane fraction, and a
supernatant, which is the cytosol fraction. The pellet
was reconstituted with the same Tris buffer. The pro-
tein concentration was assessed with a bicinchoninic
acid protein assay kit (Pierce Chemical, Rockford, IL,
USA).
Western analyses
Equal amounts of protein from vehicle-control
and drug-treated samples were separated on 10%
SDS–polyacrylamide gels. Proteins were transferred to
nitrocellulose membrane for 2 h at 100 V. Non-specific
binding to the membranes was blocked either with
TBS containing 5% (w/v) non-fat dry milk with
0.1% Tween-20 (TBST) or in PBS containing 5% (w/v)
non-fat dry milk. The following primary antibodies
were used: anti-RGS7 (1 :2000 ; polyclonal antibody,
Upstate Biotechnology Inc., Lake Placid, NY, USA),
anti-phospho-JAK2 (1 :1000 ; polyclonal antibody;
Affinity Bioreagent, Golden, CO, USA), anti-JAK2
(1 :5000 ; polyclonal antibody, Upstate Biotechnology
Inc.), and anti-actin (1 :10000; monoclonal antibody;
MP Biomedicals, Aurora, OH, USA). The secondary
antibody used for pJAK2, JAK2 and RGS7 was goat
anti-rabbit. Goat-anti mouse was used for actin pro-
tein. Prior to incubation with a second primary anti-
body, blots were stripped with Restore Western blot
stripping buffer (Pierce) by incubating at 37 xC for
25 min. After incubation, blots were removed from
stripping buffer, washed three times for 10 min each
with TBS or PBS containing 0.1% Tween-20 (TBST or
PBST) and blocked with 5% milk in TBST or PBST for
1 h at room temperature. Protein bands were analysed
densitometrically using Scion Image software (Scion
Corporation, Frederick, MD, USA). The grey scale
density readings were calibrated using a transmission
step-wedge standard. The integrated optical density
(IOD) of each band was calculated as the sum of the
optical densities of all the pixels within the area of
the band outlined. The IOD for the film background
was subtracted from the IOD for each band. Each
sample was measured in triplicate. RGS7 protein was
normalized to actin protein and phosphoproteins were
normalized to the corresponding total protein levels.
Protein levels from treated cells were normalized to
vehicle-treated cells for each Western blot analysis.
IP accumulation assay
The assay was performed as previously described
(Singh et al., 2007). Briefly, cells were seeded in 24-well
plates at a density of 40 000 cells/well. Cells were
treated with vehicle or different concentrations of
olanzapine or clozapine for 24 h in serum-free DMEM
media during the same 24-h period; cells were labelled
with 0.5 mCi [3H]myoinositol/well. Following treat-
ment and labelling, cells were washed four times with
HBSS mix containing 20 mM LiCl2, and 20 mM Hepes.
More specifically, cell culture media containing olan-
zapine and [3H]myoinositol was aspirated completely
followed by addition of washing buffer. The plate was
shaken to completely dissolve any residual media left
in the wells. Washing buffer was aspirated carefully
to remove buffer without affecting cells attached to
the plate. This step was repeated three more times
for a total of four washes ; overall, cells were washed
thoroughly four separate times to remove any residual
drug or radioactivity present on cells. Cells were then
incubated with 500 ml of the same buffer at 37 xC
for 15 min. Following the incubation, cells were chal-
lenged with 100 mM DOI for 30 min. We previously
performed a concentration response experiment exam-
ining the effects of DOI on IP accumulation in A1A1v
cells and found that the EC50 is 1 mM DOI and the
Emax is 100 mM DOI (Shi et al., 2007). In all subsequent
experiments, we have used the Emax concentration
of DOI for the IP assays in A1A1v cells. Although
DOI is also an agonist for 5-HT2C receptors, we
demonstrated that in A1A1v cells, IP accumulation
stimulated with 100 mM DOI is blocked by the
selective 5-HT2A receptor antagonist MDL 100907
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(Shi et al., 2007). Moreover, we found that A1A1v cells
do not express detectable amounts of 5-HT2C receptors
(Dai et al., 2008).
Media was replaced with 10 mM ice-cold formic
acid after the challenge treatment, and incubated on
ice for 1 h. AG1-X8 (Bio-Rad Laboratories, Hercules,
CA, USA) resin columns were prepared as follows:
columns were washed once with 3 ml of 3 M am-
monium formate/100 mM formic acid, twice with 5 ml
of 10 mM formic acid/10 mM inositol. Once the col-
umns were drained out completely, samples were
loaded into the column and allowed to enter into the
resin. Columns were then washed once with 5 ml of
10 mM formic acid/10 mM inositol, twice with 5 ml of
60 mM sodium formate/5 mM borax. After washing,
samples were eluted with 5 ml of 1 M ammonium for-
mate/100 mM formic acid into scintillation vials, 12 ml
of scintillation cocktail was added into each vial,
mixed thoroughly and counted in a scintillation
counter.
PLC assay
Since preincubation with AG490 interferes with
[3H]myoinositol incorporation into A1A1v cells, we
used an alternative, ex-vivo method to isolate mem-
branes from control and treated cells and incubated
the membrane fraction with [3H]phosphatidylinositol.
This method involves testing the enzymatic activity of
PLC present in isolated membranes thereby avoiding
any problems with incorporation of [3H]myoinositol in
presence of AG490. To harvest cells, cell culture media
was aspirated and then washed twice with ice-cold
PBS to completely remove any residual media. The
cells were scraped off the plate in Tris buffer [25 mM
Hepes–Tris, 1 mM EGTA (pH 7.4), containing protease
inhibitor cocktail] and spun at 20 000 g for 20 min at
4 xC. The pellet was resuspended in Tris buffer and
stored at x80 xC. The pellet was thawed on the day of
the PLC assay and homogenized by hand with five
up-and-down strokes with a glass-on-glass homog-
enizer and then centrifuged at 20 000 g for 20 min.
The supernatant was discarded and the pellet was re-
suspended in 50 mM Tris buffer with slow vortex to
make a complete suspension. This suspension was
then spun at 20 000 g for 10 min. The supernatant was
discarded and the pellet was resuspended in assay
buffer [25 mM Tris (pH 7.4), 3 mM EGTA, and 10 mM
LiCl) with slow vortex to make a complete suspension.
The suspension was spun at 20 000 g for 10 min to
collect a pellet. This step was repeated two more times
to complete three washes of the membrane prep-
aration before use for the PLC assay. Overall, both
treated and control cells were washed multiple times
before the membrane preparation from these cells
was used for PLC assay. 5-HT- and GTPcS-stimulated
PLC activity in cell membranes were measured as de-
scribed previously (Damjanoska et al., 2003; Wolf and
Schutz, 1997). Protein concentrations were determined
using a bicinchoninic acid protein assay kit (Pierce).
The membrane protein was diluted to an approximate
concentration of 30 mg/100 ml with buffer containing
25 mM Hepes–Tris, 3 mM EGTA, 10 mM LiCl, 12 mM
MgCl2, 1.44 mM sodium deoxycholate with 0.5 mM
GTPcS (a non-hydrolysable form of GTP), 100 nM
free Ca2+, 1 mM unlabelled phosphatidylinositol, and
100 mM [3H]phosphatidylinositol (PerkinElmer Life
and Analytical Sciences, Waltham, MA, USA). A con-
centration of 100 mM 5-HT or 1 mM of bradykinin
was used to stimulate PLC activity. 5-HT-stimulated
PLC activity is a selective measure of 5-HT2A receptor
function in A1A1v cells as previously demonstrated
using selective antagonists (Shi et al., 2007). Bradykinin
was used to investigate the selectivity of olanzapine-
induced desensitization of 5-HT2A receptor signalling.
RNA isolation and reverse transcription
Total RNA was isolated using the RNeasy Mini kit
(Qiagen Sciences, Valencia, CA, USA) according to the
manufacturer’s protocol. Total RNA was quantitated
using a spectrophotometer and optical density (OD)
260/280 nm ratios were determined. Quality of the
RNA was further accessed with a formaldehyde-
agarose gel. First-strand cDNA was synthesized using
random hexamers and Superscript II Reverse
Transcriptase from Invitrogen (Carlsbad, CA, USA)
according to the manufacturer’s protocol. Reactions
were incubated at 25 xC for 2 min, 25 xC for 10 min,
and 42 xC for 50 min and inactivated by heating at
70 xC for 15 min in an M J Mini, personal thermal
cycler (Bio-Rad).
Real-time PCR
The GAPDH (sense : 5k-tggagtctactggcgtcttcac-3k ; anti-
sense : 5k-ggcatggactgtggtcatga-3k) and RGS7 (sense : 5k-
gaagatgagttgcaccgacaga-3k ; antisense: 5k-ggtctttcagtg-
cctcatccat-3k) primer sets were synthesized by IDT
Inc. (Coralville, IA, USA). PCR amplification was per-
formed with 7500 Real-Time PCR System using SYBR
Green PCR master mix (Applied Biosystems, Foster
City, CA, USA). The PCR parameters used were a
10 min denaturation cycle at 95 xC, 40 cycles of ampli-
fication at 95 xC for 15 s, and annealing/extension at
60 xC for 1 min. Real-time PCR was performed with
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25 ml reaction mixture of cDNA, primers and SYBR
Green master mix.
RNA data analysis
Comparative CT (DDCT) method was used for analysis
of all real-time PCR data. DCT values were calcu-
lated by normalizing CT values of RGS7 to GAPDH
from vehicle- and antagonist-treated groups. The
extent of the response is determined by 2mean(DDCT),
and the relative degree of response is calculated by
2xmean(DDCT). Results are expressed as fold change in
RGS7 mRNA levels for clozapine-, MDL 100907- or
olanzapine-treated cells with respect to vehicle-treated
cells. Data presented are from four independent ex-
periments performed in triplicate.
Chromatin immunoprecipitation (ChIP) assay
The ChIP assay was performed using a kit (Millipore,
Billerica, MA, USA) according to the manufacturer’s
protocol. Following crosslinking, the DNA/protein
complexes were sheared by sonication. One percent of
sheared DNA/protein complex was kept and used as
an input DNA sample. Anti-STAT3 rabbit polyclonal
antibody (Sigma, St Louis, MO, USA), or normal rabbit
IgG (Millipore) was used for immunoprecipitation.
Immunoprecipitated DNA/protein complexes were
analysed using polymerase chain reaction (PCR)
with following primer sets flanking the five potential
STAT3 binding sites (sites 1–5) :
F1 : 5k-GAAGTCAGGAGTCAGTCAAAGC-3k,
R1 : 5k- ACTCCTTGGCTTCAACTATGG-3k,
F2 : 5k-AAGCTGGGTACGTTTCAGG-3k,
R2 : 5k-AATTTGGAGGCCTGGACC-3k,
F3 : 5k-ATCCTTGGCACTGGACACC-3k,
R3 : 5k-GGGCTAAGATAATGGGAGG-3k,
F4 : 5k-GATGGTTTGCCACTTGTGC-3k,
R4 : 5k- CTACTCTGCAGCCATCTGC-3k,
F5 : 5k- ACATTCCAACAGGACCGG-3k
R5: 3’-ATCGGTCATGGCATCTCACC-3k.
A previously identified STAT3 binding region
from the hepcidin gene was a positive control (F : 5k-
GAGGGTGACACAACCCTGTT-3k, R : 5k-ACCGAG-
TGACA GTCGCTTTT-3k) (Wrighting and Andrews,
2006). Two microlitres of precipitated DNA was
amplified using Taq polymerase (New England Bio-
labs, Ipswich, MA, USA). The conditions for PCR
amplification were as follows: 40 cycles of 94 xC for
15 s, 55 xC for 15 s, 72 xC for 45 s, and the amplimers
were resolved on 1% agarose gels containing ethidium
bromide.
Statistics
All statistical analyses were performed using GB-
STAT School Pak (Dynamic Microsystems, Silver
Spring, MD, USA). Data are expressed as means¡
S.E.M. For Western blots and IP accumulation assay,
data were analysed using a using a one-way analysis
of variance (ANOVA), followed by a Newman–Keuls
post-hoc analysis. RT–PCR and PLC activity assay was
analysed using a two-way ANOVA, followed by a
Newman–Keuls post-hoc analysis.
Results
IP accumulation assay
Agonist-stimulated IP accumulation can be used to
monitor desensitization of 5-HT2A receptor signalling
(Singh et al., 2007). Treatment with olanzapine for
24 h significantly decreased (F3,8=49.83, p<0.0001)
DOI (10x4 M)-stimulated IP accumulation in a dose-
dependent manner. Treatment with 30 nM, 300 nM or
3000 nM of olanzapine decreases the amount of IP by
y13% (p<0.05), 27% (p<0.01) or 51% (p<0.01), re-
spectively, compared to vehicle (acetic acid)-treated
cells (Figure 1a). A similar effect on IP accumulation
was also observed when cells were treated with
clozapine at a higher concentration range. We found
that treatment with increasing concentrations of clo-
zapine for 24 h significantly decreased (F4,14=104.43,
p<0.0001) DOI-stimulated IP accumulation in a dose-
dependent manner compared to vehicle (DMSO)-
treated cells (Figure 1b). A post-hoc analysis revealed
a decrease in IP accumulation by 39% with 5 mM
(p<0.01), 53% with 20 mM (p<0.01), 64% with 30 mM
(p<0.01), and 80% with 40 mM (p<0.01) treatment.
Subsequent experiments used 20 mM clozapine based
on this dose resulting in a reduction ofy50% of the IP
accumulation. These decreases suggest a desensitiza-
tion of 5-HT2A-mediated receptor signalling in A1A1v
cells by olanzapine or clozapine.
Clozapine and MDL 100907 treatment increased
phosphorylation of JAK2 and pretreatment with
AG490 abolished this effect
We have shown that the 5-HT2A receptor inverse
agonist, olanzapine causes phosphorylation of JAK2
kinase (Singh et al., 2007). In order to investigate
whether the effect is specific to olanzapine or is a gen-
eral effect of atypical antipsychotics and more specifi-
cally 5-HT2A receptor antagonists, we treated A1A1v
cells for 24 h with either clozapine, MDL 100907 or
drug vehicles. Membrane fractions prepared from
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vehicle-, clozapine (20 mM)-, and MDL 100907 (1 mM)-
treated cells were analysed by Western blot with an
anti-phospho-JAK2 antibody, then stripped and re-
probed with an anti-JAK2 antibody (Figure 2a).
Tyrosine phosphorylation of JAK2 was significantly
increased (F2,8=39.57, p<0.001). A post-hoc analysis
revealed that pJAK levels were increased to 183
¡13% of the control levels with MDL 100907-treated
cells and 196¡18% of the control levels with cloza-
pine-treated cells, whereas total JAK2 protein levels
did not show any appreciable change. To investi-
gate whether inhibition of the JAK-STAT signalling
cascade could reverse the increase of phosphorylation
of JAK2 observed in response to clozapine or
MDL 100907 treatment, cells were pretreated for 1 h
with 30 mM AG490, a JAK kinase inhibitor, prior to
incubation with either clozapine or MDL 100907 for
24 h. As shown in Figure 2b, the clozapine- or
MDL 100907-induced increase in phosphorylation of
JAK2 was blocked by AG490 pretreatment. Two-way
ANOVA indicates a significant main effect of AG490
pretreatment (F1,12=1469.36, p<0.001), a significant
main effect of clozapine or MDL 100907 incubation
(F2,12=22.28, p<0.01) on JAK2 phosphorylation and
a significant interaction between these two factors
(F2,12=35.75, p<0.01). JAK2 phosphorylation is sig-
nificantly greater in cells incubated with clozapine or
MDL 100907 and pretreated with vehicle compared to
the other four groups (p<0.01).
Pretreatment with AG490 prevented clozapine-
and MDL 100907-induced increases in RGS7
protein levels
Next, we wanted to determine whether this increase
in JAK2 phosphorylation with both clozapine and
MDL 100907 is also accompanied by increases in
RGS7 protein levels as previously observed with
olanzapine. In order to monitor the changes in
RGS7 protein levels, membrane fractions of vehicle-,
clozapine-, or MDL 100907-treated cells were analysed
by Western blot with anti-RGS7 antibody (Figure 3a).
We found that RGS7 protein levels were significantly
increased (F2,8=95.99, p<0.001) by drug treatments.
A post-hoc analysis revealed that RGS7 protein
levels were increased to 176¡16% of the control levels
with MDL 100907-treated cells and 194¡11% in clo-
zapine-treated cells. Pretreatment with AG490 for 1 h
inhibits the increase of RGS7 protein in response
to clozapine or MDL 100907 stimulation (Figure 3b).
Two-way ANOVA indicates a significant main effect
of AG490 pretreatment (F1,12=20.05, p<0.05), a sig-
nificant main effect of clozapine or MDL 100907 incu-
bation (F2,12=13.14, p<0.05) on RGS7 and a significant
interaction between these two factors (F2,12=12.06,
p<0.05). RGS7 is significantly increased in cells
treated with clozapine or MDL 100907 and pretreated
with vehicle compared to the other four groups
(p<0.05).
JAK2 phosphorylation preceded the increase in RGS7
protein in response to olanzapine
We previously demonstrated that olanzapine causes
phosphorylation of JAK2 kinase and STAT3, and
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Figure 1. Olanzapine or clozapine decreases DOI-stimulated
inositol phosphate (IP) accumulation. A1A1v cells were
treated with either vehicle or with various concentrations of
(a) olanzapine or (b) clozapine for 24 h, and incubated with
[3H]myoinositol for the same 24 h period. Then cells were
stimulated with 10x4 M DOI. The bar graph represents IP
accumulation normalized to DOI-stimulated IP accumulation
in vehicle-treated cells from at least three independent
experiments. IP accumulation was significantly decreased in
olanzapine- or clozapine-treated cells compared to vehicle-
treated cells. * Indicates significantly different from vehicle-
treated cells at p<0.05 ; ** indicates significantly different
from vehicle-treated cells at p<0.01 ; # indicates significantly
different from 5 mM clozapine at p<0.05 as analysed by
one-way ANOVA and Newman–Keuls post-hoc tests.
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increases RGS7 protein, suggesting that olanzapine-
induced activation of the JAK-STAT signalling cas-
cade leads to increased expression of RGS7 protein
(Singh et al., 2007). To further explore the underlying
mechanism, we treated cells with olanzapine (300 nM)
or vehicle (20% acetic acid) for 3, 6, 12 or 24 h. Lysates
of membrane fractions were examined by Western
blot with anti-phospho-JAK2, or anti-RGS7 antibody,
then stripped and reprobed with anti-JAK2 or anti-
actin antibody (Figure 4). For JAK2 phosphorylation,
two-way ANOVA indicates a significant main effect
of olanzapine treatment (F1,16=83.63, p<0.05), a sig-
nificant main effect of time-course (F3,16=21.57, p<
0.01) and a significant interaction between these two
factors (F3,16=10.22, p<0.01). Newman–Keuls mul-
tiple comparison test indicates tyrosine phosphoryla-
tion of JAK2 was significantly elevated after 3, 6, 12 or
24 h of olanzapine treatment compared to vehicle-
treated cells at the same time-point (p<0.01). A peak
of JAK2 phosphorylation was detected at 6 h of
stimulation with olanzapine. There is no significant
difference in total JAK2 protein levels (Figure 4a).
For RGS7 protein levels, two-way ANOVA indicates
a significant main effect of olanzapine treatment
(F1,16=133.44, p<0.01), a significant main effect of
time-course (F3,16=10.71, p<0.01) and a significant
interaction between these two factors (F3,16=9.18,
p<0.05). A post-hoc analysis revealed RGS7 was only
increased after 24 h of olanzapine treatment (p<0.01)
compared to 24 h for vehicle-treated cells (Figure 4b).
There is no significant difference in RGS7 protein
levels between vehicle-treated cells and cells treated
for 3, 6, or 12 h with olanzapine.
JAK2 inhibitor partially reversed the olanzapine-
induced desensitization of 5-HT2A receptor signalling
We have previously shown that the olanzapine-
induced activation of the JAK2-STAT3 pathway is
necessary for the increase in RGS7 protein levels ; next
we wanted to determine if activation of the JAK2-
STAT3 pathway is necessary for olanzapine-induced
desensitization of 5-HT2A receptor signalling. How-
ever, AG490 interfered with the measurements of IP
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Figure 2. Clozapine and MDL 100907 stimulate JAK2 phosphorylation and pretreatment with AG490 reverses this effect. (a)
A1A1v cells were treated either with vehicle (DMSO) or 20 mM clozapine or 1 mM MDL 100907 for 24 h. Membrane fractions of
cells were analysed by Western blot with anti-phospho-JAK2 antibody, stripped and reprobed with anti-JAK2 and anti-actin
antibodies. The bar graph represents quantification of phospho-JAK2 protein levels divided by JAK2 protein levels from five
independent experiments. Phosphorylation of JAK2 was significantly increased (p<0.05) with both clozapine and MDL 100907
treatment compared with vehicle-treated cells (* indicates significantly different from vehicle-treated cells at p<0.05). (b) Cells
were pretreated with AG490 (30 mM) for 1 h before treatment with either MDL 100907 or clozapine for 24 h. Membrane fractions
of cells were analysed as described above. The bar graph represents quantification of phospho-JAK2 protein levels divided by
JAK2 protein levels from three independent experiments (# indicates significantly different from vehicle-pretreated and the same
drug-treated cells at p<0.01 ; * indicates significantly different from vehicle-pretreated and vehicle-treated cells at p<0.01 as
analysed by two-way ANOVA and Newman–Keuls post-hoc tests).
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Figure 3. Pretreatment with AG490 prevented the clozapine- and MDL 100907-induced increase in RGS7 protein levels. (a)
A1A1v cells were treated either with vehicle (DMSO) or 20 mM clozapine or 1 mM MDL 100907 for 24 h. Membrane fractions of
cells were analysed by Western blot with an anti-RGS7 antibody, stripped and reprobed with an anti-actin antibody as a
loading control. Bar graph represents quantification of RGS7 protein levels divided by actin protein levels from four
independent experiments. RGS7 protein levels were significantly increased (p<0.05) with clozapine and MDL 100907 compared
to vehicle-treated cells (* indicates significantly different from vehicle-treated cells at p<0.05). (b) Cells were pretreated with
AG490 (30 mM) for 1 h before treatment with either MDL 100907 or clozapine for 24 h. Membrane fractions of cells were analysed
as described above. Bar graph represents quantification of RGS7 protein levels divided by actin protein levels from three
independent experiments (# and ## indicates significantly different from vehicle-pretreated and the same drug-treated cells at
p<0.05 and p<0.01 respectively ; * indicates significantly different from vehicle-pretreated and vehicle-treated cells at p<0.05 as
analysed by two-way ANOVA and Newman–Keuls post-hoc tests).
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Figure 4. Time-course studies show JAK2 phosphorylation preceded the increase in RGS7 protein in response to olanzapine.
(a) Cells were treated with olanzapine (300 nM) or vehicle (20% acetic acid) for 3, 6, 12 or 24 h. Membrane fractions of cells
were analysed by Western blot with anti-phospho-JAK2, then stripped and reprobed with anti-JAK2 antibody. The bar graph
represents quantification of phospho-JAK2 protein levels divided by JAK2 protein levels from three independent experiments
(* indicates significantly different from vehicle-treated cells at the same time-point at p<0.01 ; # and ## indicate significantly
different from 3 h olanzapine-treated cells at p<0.05 and p<0.01 respectively ; + indicates significantly different from 6 h
olanzapine-treated cells at p<0.01). (b) The same membrane was stripped and reprobed with anti-RGS7 and anti-actin antibody.
Bar graph represents quantification of RGS7 protein levels divided by actin protein levels from three independent experiments
(* indicates significantly different from vehicle-treated cells at the same time-point at p<0.01 ; # indicates significantly different
from 3 h olanzapine-treated cells at p<0.01 as analysed by two-way ANOVA and Newman–Keuls post-hoc tests).
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accumulation in vivo. Therefore, we decided to use
an alternative ex-vivo method in which we isolated
membranes from AG490-pretreated, control and
olanzapine-treated cells and then incubated them with
[3H]phosphatidylinositol. This method involves mea-
suring the enzymatic activity of PLCpresent in isolated
membranes thereby avoiding any interference of pre-
incubation of AG490 on incorporated [3H]myoinositol.
Olanzapine-induced changes in PLC activity were
monitored in response to stimulation with 5-HT,
bradykinin, or GTPcS. Basal activity was 241.6 pmol/
mg protein per min whereas 5-HT-stimulated PLC
activity measurement was 2431.0 pmol/mg protein
per min. 5-HT stimulation measures the ability of
5-HT2A receptors to stimulate PLC activity via Gaq/11
activation where as GTPcS directly binds to Gaq/11 to
activate PLC. Bradykinin was used to investigate
the specificity of olanzapine-induced desensitization
response by examining the effects on another Gaq/11
linked receptor system. Olanzapine treatment signifi-
cantly decreased (by 55%, p<0.01) PLC activity
stimulated with 5-HT. AG490 alone had no effect
on PLC activity (Figure 5a). However, pretreatment
with AG490 significantly attenuated the olanzapine-
induced decreases in PLC activity (p<0.05) suggesting
that the JAK-STAT pathway is necessary for the full
olanzapine-induced desensitization of 5-HT2A recep-
tor signalling. Two-way ANOVA indicates a main
effect of olanzapine on PLC activity (F1,19=41.18, p<
0.001), a main effect of AG490 (F1,19=4.23, p<0.05),
but no significant interaction was observed between
olanzapine and AG490 (F1,19=2.92, p<0.391). In ad-
dition, olanzapine or AG490 treatment had no effect on
GTPcS-stimulated PLC activity (Figure 5b). Olanzapine
treatment had no effect on bradykinin-stimulated
PLC activity confirming that olanzapine treatment
specifically desensitizes 5-HT2A receptor signalling
(Figure 5c).
Olanzapine, clozapine and MDL 100907 increase
RGS7 mRNA levels
To investigate whether the increase in RGS7 protein
levels is associated with an increase in RGS7 mRNA
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Figure 5. A JAK inhibitor partly attenuated the olanzapine-
induced decrease in PLC activity. A1A1v cells were
pretreated for 1 h with 30 mM AG490 prior to treating with
either vehicle (20% acetic acid) or 300 nM olanzapine for 24 h.
(a) 5-HT-stimulated PLC activity was significantly (p<0.01)
reduced by olanzapine treatment compared to vehicle-
treated control (** indicates significantly different at p<0.01).
AG490 alone did not have any effect on PLC activity as
analysed by two-way ANOVA and Newman–Keuls post-hoc
tests. However, in cells pretreated with AG490, the
olanzapine-induced decrease in PLC activity was
significantly attenuated (* indicates significantly different at
p<0.05). (b) GTPcS-stimulated PLC activity was not altered
either by the olanzapine or AG490 treatments. (c) Olanzapine
treatment had no effect on bradykinin-stimulated PLC
activity, whereas 5-HT-stimulated PLC activity was
significantly reduced suggesting olanzapine treatment
selectively affect 5-HT2A receptor-mediated PLC activity as
analysed by two-way ANOVA and Newman–Keuls post-hoc
tests. Experiments were performed three independent times.
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levels, cells were treated in a similar fashion as in pre-
vious experiments for 24 h with vehicle, olanzapine,
clozapine, or MDL 100907. Total RNA was isolated
from each sample and reverse-transcribed with ran-
dom hexamers to make cDNA. Using that cDNA, a
real-time PCR analysis was performed with specific
primers for RGS7 and GAPDH. The vehicle and drug-
treated RGS7 mRNA levels were normalized to
GAPDH. We found a statistically significant (F1,15=
43.43, p<0.001) increase in RGS7mRNA levels. A post-
hoc analysis revealed that RGS7 mRNA levels were
increased to 153¡11% with olanzapine (Figure 6a),
175¡14% with clozapine, and 144¡17% with MDL
100907 treatment (Figure 6b) over their respective
vehicle-treated cells.
STAT3 binds to the putative RGS7 promoter region
To determine if STAT3 binds to potential STAT3 con-
sensus sites in cells, we used a ChIP approach. A
bioinformatic analysis of the 10 kb promoter region of
rat RGS7 identified five potential STAT3-binding sites
based on the consensus sequence TTCN2-4GAA. Spe-
cific primers were designed that flank each of these
consensus sites and were named site numbers 1–5
(Figure 7). A1A1v cells were treated with vehicle (20%
acetic acid) or olanzapine (300 nm) for 24 h as pre-
viously described. Immunoprecipitates isolated from
either vehicle- or olanzapine-treated cells were used to
perform ChIP analysis. Of the five potential STAT3-
binding sites identified, only site 2 tested positive in
this analysis (Figure 7), while the other primers failed
to result in binding to either the immunoprecipitated
DNA or the input DNA. Moreover, treatment with
olanzapine appeared to increase STAT3 binding at this
site. However, this approach is only semi-quantitative
so no attempt was made to quantify the increase in
band intensity in the olanzapine-treated lanes. Site 2
begins 2.34 kb upstream of the RGS7 transcription
start site. Negative control primers did not produce an
amplimer using immunoprecipiatated chromatin
(data not shown). The primers specific for hepcidin,
used as a positive control, also tested positive using
immunoprecipitated STAT3. In contrast, when the
beads alone or pre-immune IgG was used in the
immunoprecipitation procedure, no amplimer was
detected.
Discussion
Atypical antipsychotics have been previously re-
ported to act as inverse agonists and to induce de-
sensitization of 5-HT2A receptor signalling (Egan et al.,
1998, 2000 ; Herrick-Davis et al., 1998; Rauser et al.,
2001). Internalization and down-regulation have been
proposed asmechanisms of desensitization (Roth et al.,
1995 ; Willins et al., 1998) however, subsequent studies
provided evidence supporting both internalization-
and down-regulation-dependent and independent
desensitization of 5-HT2A receptors by atypical anti-
psychotics (Hanley and Hensler, 2002 ; Kuoppamaki
et al., 1995). It is likely that internalization and down-
regulation can contribute to the desensitization
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Figure 6. Olanzapine, clozapine and MDL 100907 increase
RGS7 mRNA levels. A1A1v cells were treated either with
vehicle (20% acetic acid), 300 nM olanzapine, vehicle (DMSO),
20 mM clozapine or 1 mM MDL 100907 for 24 h. Total RNA was
isolated from vehicle-treated control or drug-treated cells,
and equal amounts of cDNA were reverse-transcribed. Bar
graph represents quantification of RGS7 mRNA levels
normalized to GAPDH levels from five independent
experiments and represents the fold change over control.
RGS7 mRNA levels were significantly increased in
olanzapine-, clozapine- and MDL 100907-treated compared
to vehicle-treated cells (p<0.05) as analysed by two-way
ANOVA and Newman–Keuls post-hoc tests (* indicates
significantly different from vehicle-treated cells at p<0.05).
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process but whether they are necessary and sufficient
for the full desensitization process is not known.
In addition, studies were inconclusive regarding the
role for transcriptional regulation of 5-HT2A receptor
down-regulation with antipsychotics (Gray and Roth,
2001). Both, a decrease in receptor mRNA in hippo-
campus, brainstem, and midbrain and no change in
mRNA levels have been previously reported with
atypical antipsychotics (Burnet et al., 1996 ; Doat-
Meyerhoefer et al., 2005). Thus, transcriptional regu-
lation of 5-HT2A receptors by atypical antipsychotics
does not appear to be responsible for down-regulation
leading to the desensitization of 5-HT2A receptor sig-
nalling.
Consistent with previous reports that atypical
antipsychotics induce desensitization of 5-HT2A re-
ceptor signalling (Gray and Roth, 2001) we find that
olanzapine and clozapine induce desensitization of
5-HT2A receptor-stimulated PLC activity in A1A1v
cells. Olanzapine, clozapine, andMDL 100907 increase
RGS7 mRNA and protein levels as well as the acti-
vation of the JAK-STAT pathway. We previously
found that the increase in RGS7 protein expression
in response to olanzapine treatment is dependent
on JAK-STAT signalling (Singh et al., 2007). We now
report that the increase in RGS7 protein induced
by clozapine and MDL 100907 is dependent on acti-
vation of the JAK-STAT signalling pathway as well.
Furthermore, activation of the JAK-STAT pathway by
olanzapine occurs prior to the increase in RGS7 pro-
tein levels. Most importantly, we now further report
that a major component of the desensitization re-
sponse on 5-HT2A receptor signalling, induced by
these atypical antipsychotics is dependent on JAK-
STAT signalling. Olanzapine-induced decreases in
PLC activity, monitored as an index of 5-HT2A recep-
tor responsiveness (i.e. desensitization), were signifi-
cantly attenuated by pretreatment with a JAK2 kinase
inhibitor. These data suggest that activation of the
JAK-STAT pathway is necessary for the full atypical
antipsychotic-induced desensitization of the 5-HT2A
receptor-stimulated PLC response, however, receptor
down-regulation and internalization probably also
contribute to the desensitization of 5-HT2A receptor
signalling.
In addition to 5-HT2A receptors, atypical anti-
psychotics also have high affinity for other G protein-
coupled receptors, e.g. other 5-HT receptors (e.g.
5-HT1A, 5-HT2C, 5-HT6, and 5-HT7) (Meltzer et al., 1989;
Meltzer, 1999 ; Roth et al., 1992 ; Seeger et al., 1995), the
dopamine D4 receptor (Roth et al., 1995 ; Van Tol et al.,
1991), all five muscarinic receptors (m1–m5) (Peroutka
and Synder, 1980 ; Zeng et al., 1997), and several adre-
nergic and histamine receptors (Peroutka and Synder,
1980). MDL 100907 initially characterized as a selective
antagonist of the 5-HT2A receptor, has been used to
delineate antipsychotic responses mediated specifi-
cally by the 5-HT2A receptor (Bhagwagar et al., 2006 ;
Olijslagers et al., 2005 ; Wolff and Leander, 2000) and
desensitizes 5-HT2A receptor signalling (Rauser et al.,
2001). In the present study, we report that MDL 100907
stimulated activation of the JAK-STAT pathway and
increased RGS7 protein and mRNA levels suggesting
that antagonism of 5-HT2A receptors is sufficient to
induce these changes. Similar effects could be caused
by antagonism of 5-HT2A receptors by olanzapine and
600 bp
Site 2 Hepcidin
STAT3
binding
Beads IgG Oln Veh Oln Veh
STAT3
Positive
ctrlInput
Five potential STAT3
binding sites 5 4 3 2 1
Start
Figure 7. STAT3 binds to the putative RGS7 promoter region at site 2. ChIP assays were performed as described in the Materials
and Methods section with an anti-STAT3 antibody, non-immune IgG, or with beads alone. Primers that amplify the STAT3
binding site previously identified in the hepcidin gene were used as a positive control. Non-precipitated genomic DNA (input)
was used as a positive control. Amplification was not observed in lanes loaded with samples immunoprecipitated with beads
alone, i.e. without the STAT3 antibody, and non-specific IgG in place of the STAT3 antibody confirming specificity of the reaction
with the STAT3 antibody.
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clozapine, although the binding of these atypical anti-
psychotics to other receptors could also contribute to
responses and cannot be ruled out.
RGS proteins reduce G-protein-mediated signal-
ling by acting as guanosine triphosphatase (GTPase)-
accelerating proteins (GAPs) for Ga subunits and by
blocking the interaction of Ga subunits with effectors
(Dohlman and Thorner, 1997 ; Hollinger and Hepler,
2002). Expression of RGS7 protein in rat frontal cortex
is well documented (Krumins et al., 2004 ; Zhang
and Simonds, 2000) and decreased 5-HT2A receptor
signalling via direct interaction of RGS7 protein
with Gaq has been characterized in different systems
(DiBello et al., 1998 ; Ghavami et al., 2004). Fur-
thermore, an increase in RGS7 protein following both
olanzapine and clozapine treatment would increase
the termination rate of 5-HT2A receptor-Gaq/11 protein
signalling by more rapidly hydrolysing GTP, and
could thereby produce or contribute to the desensitiz-
ation response. However, since GTPcS is a non-
hydrolysable GTP analogue, PLC activity stimulated
by GTPcS alone would not be expected to be affected
by RGS proteins. Indeed, as shown in Figure 5b,
GTPcS-stimulated PLC activity was not altered by the
increase in RGS7 protein that occurs with olanzapine
treatment. Therefore, the differential effects of olanz-
apine on receptor vs. G-protein activation of PLC ac-
tivity are consistent with an increase in RGS7 protein
either acting as a GAP for endogenous GTP induced
by 5-HT to bind to Gaq/11 or by possibly blocking in-
teraction of Gaq/11 with 5-HT2A receptors. Previous
studies have demonstrated that RGS proteins can
block the interaction of Ga subunits with effectors
(Hollinger and Hepler, 2002 ; Ross and Wilkie, 2000)
and so RGS7 could conceivably block the interaction of
Gaq/11 with receptors. Further studies are needed to
determine the mechanisms by which RGS7 is affecting
the system.
Numerous studies have reported a significant de-
crease in RGS4 expression in the prefrontal cortex of
schizophrenia subjects (Bowden et al., 2007 ; Erdely
et al., 2006 ; Gu et al., 2007 ; Mirnics et al., 2001).
Expression of RGS4 and RGS7 have been previously
noted to be independent (Krumins et al., 2004). Like
RGS7 proteins, RGS4 also regulates 5-HT2A receptor
signalling. Atypical antipsychotic-induced increases
in RGS7 levels observed in our studies might restore
the 5-HT2A receptor signalling duration to physio-
logical levels by substituting for the diminished RGS4
protein in schizophrenia patients.
Atypical antipsychotics could increase RGS7 levels
by either increased stability of RGS7 protein or by
increased transcription of RGS7 mRNA. RGS7 binding
to Gb5 is reported to increase the stability of each
protein (Chen et al., 2003 ; Krumins et al., 2004). In
addition, RGS7 phosphorylation and subsequent
binding to 14-3-3 sequesters RGS7 in the cytoplasm
(Burchett, 2003). Therefore, an increase in phospho-
rylation of RGS7 or increased expression of 14-3-3
or Gb5 could increase the levels of RGS7 in the
cytoplasm. Our real-time PCR data suggest that the
increase in RGS7 levels by olanzapine, clozapine
and MDL 100907 could be directly mediated by an
increase in RGS7 mRNA via activation of the JAK-
STAT pathway. STAT3 regulates a variety of biologi-
cal processes, functioning at both transcriptional and
non-transcriptional levels to influence cell growth,
survival and metabolism (Inghirami et al., 2005;
Leeman et al., 2006). From a genomic sequence analy-
sis of rat RGS7, we have identified multiple sets of the
STAT3 consensus binding element, TTCN2-4GAA
(Decker et al., 1997 ; Ehret et al., 2001), suggesting that
STAT3 could be a possible transcription factor for the
RGS7 promoter. Using a ChIP analysis, we found one
of the STAT3 consensus binding elements located
2.34 kb upstream of the transcription start site strongly
binds with STAT3 in response to olanzapine treat-
ment. STAT3 binding to the RGS7 gene along with an
increase in mRNA levels of RGS7 suggests the possi-
bility that STAT3 is a transcription factor for RGS7.
The promoter region of RGS7 is not yet identified,
however, it is usually present upstream of the tran-
scription start site consistent with our identified
STAT3 binding site 2.34 kb upstream from the tran-
scription initiation site. Taken together, these results
are consistent with our hypothesis that activation of
the JAK-STAT pathway by atypical antipsychotics and
the subsequent increase in RGS7 expression is an
underlying mechanism for desensitization of 5-HT2A
receptor signalling.
In our previous studies (Muma et al., 2007 ; Singh
et al., 2007) we have reported olanzapine-induced
activation of the JAK-STAT pathway. In the present
study we demonstrate that activation of the JAK-STAT
pathway is necessary for full desensitization of 5-HT2A
receptor signalling by atypical antipsychotics in
A1A1v cells. While the precise mechanism of the
JAK-STAT activation by atypical antipsychotics is
not determined, it has been reported that 5-HT2A re-
ceptor associates in a complex with JAK2 and Stat3
(Guillet-Deniau et al., 1997). Other studies have re-
ported that 5-HT activates JAK2, JAK1, and STAT1 via
5-HT2A receptors (Banes et al., 2005). Furthermore,
atypical antipsychotics have also been reported to
activate other signalling cascades for example, activa-
tion of ERK1/2 pathways in the rat frontal cortex
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(Fumagalli et al., 2006), Akt/PKB and P38 pathways in
PC12 cells (Lu et al., 2004), and GSK3a/b in the rat
frontal cortex (Kang et al., 2004 ; Roh et al., 2007).
Although atypical antipsychotics have been exten-
sively characterized as inverse agonist/antagonists of
5-HT2A receptors, activation of the JAK-STAT pathway
in our studies clearly indicates that besides being an
antagonist, atypical antipsychotics are also an agonist
for the JAK-STAT pathway. Our studies demonstrate
that agonist activity as demonstrated by activation of
the JAK-STAT pathway and antagonist effects at the
PLC enzyme occur simultaneously. Previous studies
have demonstrated selective agonism, where one
agonist stimulates one pathway preferentially over
another (Kenakin, 2007). Our studies extend the diver-
sity of signalling by a single receptor suggesting that
a ligand like MDL 100907 can be an agonist for one
5-HT2A receptor-mediated pathway, JAK-STAT, and
simultaneously an antagonist at the Gaq/11-PLC path-
way.
Overall, our data suggest that desensitization of
5-HT2A receptor-stimulated PLC activity by olanza-
pine, clozapine and MDL 100907 requires activation of
the JAK-STAT pathway. In addition, activation of the
JAK-STAT pathway and increases in RGS7 expression
by transcriptional activity of STAT3 are likely to con-
tribute to the full desensitization response of 5-HT2A
receptor signalling. However, further studies are
needed to confirm the transcriptional activity of
STAT3 on the putative promoter site of RGS7.
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